Evidence map›Paper›PMID 38455055›Full record

ArticleFrontiers in immunology2024

Mapping of a hybrid insulin peptide in the inflamed islet β-cells from NOD mice.

Janet M Wenzlau, Orion J Peterson, Anthony N Vomund, James E DiLisio, Anita Hohenstein, Kathryn Haskins, Xiaoxiao Wan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Janet M WenzlauDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Orion J PetersonDivision of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.
Anthony N VomundDivision of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.
James E DiLisioDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Anita HohensteinDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Kathryn HaskinsDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Xiaoxiao WanDivision of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.
University of Colorado Denver · USWashington University in St. Louis · US

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Christine T. Pham · 2018 to 2026
$7.6M
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T CellsR01DK081166 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HASKINS, KATHRYN M, JAMES, EDDIE A · 2011 to 2024
$7.3M
The role of beta-cell crinophagy in generating diabetogenic neoepitopesR01DK134437 · NIDDK · WASHINGTON UNIVERSITY · PI Xiaoxiao Wan · 2023 to 2026
$2.4M
Autoimmune Diabetes: Macrophage ResponsesR01AI162591 · NIAID · WASHINGTON UNIVERSITY · PI Xiaoxiao Wan · 2022 to 2026
$2.3M
Autoantibodies to hybrid insulin peptides in type 1 diabetesR21AI132907 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HASKINS, KATHRYN M · 2018 to 2019
$428k
NIAID NIH HHS R01 AI162591NIAID NIH HHS R21 AI132907NIAMS NIH HHS P30 AR073752NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK081166NIDDK NIH HHS R01 DK134437
6 · The paper itself

Abstract

There is accumulating evidence that pathogenic T cells in T1D recognize epitopes formed by post-translational modifications of β-cell antigens, including hybrid insulin peptides (HIPs). The ligands for several CD4 T-cell clones derived from the NOD mouse are HIPs composed of a fragment of proinsulin joined to peptides from endogenous β-cell granule proteins. The diabetogenic T-cell clone BDC-6.9 reacts to a fragment of C-peptide fused to a cleavage product of pro-islet amyloid polypeptide (6.9HIP). In this study, we used a monoclonal antibody (MAb) to the 6.9HIP to determine when and where HIP antigens are present in NOD islets during disease progression and with which immune cells they associate. Immunogold labeling of the 6.9HIP MAb and organelle-specific markers for electron microscopy were employed to map the subcellular compartment(s) in which the HIP is localized within β-cells. While the insulin B9-23 peptide was present in nearly all islets, the 6.9HIP MAb stained infiltrated islets only in NOD mice at advanced stages of T1D development. Islets co-stained with the 6.9HIP MAb and antibodies to mark insulin, macrophages, and dendritic cells indicate that 6.9HIP co-localizes within insulin-positive β-cells as well as intra-islet antigen-presenting cells (APCs). In electron micrographs, the 6.9HIP co-localized with granule structures containing insulin alone or both insulin and LAMP1 within β-cells. Exposing NOD islets to the endoplasmic reticulum (ER) stress inducer tunicamycin significantly increased levels of 6.9HIP in subcellular fractions containing crinosomes and dense-core granules (DCGs). This work demonstrates that the 6.9HIP can be visualized in the infiltrated islets and suggests that intra-islet APCs may acquire and present HIP antigens within islets.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsIslets of LangerhansAnimalsAntigensMiceMice, Inbred NODPeptidesAntigensPeptidesantigenautoimmune diabeteshybrid insulin peptideisletsNODpost-translational modificationtype 1 diabetesβ-cells

Identifiers

PMID38455055
PMCPMC10917911
OpenAlexW4392057504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.